YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings? ResMed currently trades at $218.94 per share and has shown little upside over the past six months, posting a small loss of 2.7%. The stock also fell short of the S&P 500's 15.9% gain durin…
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, lead…
Resmed, Inc. SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the…
Glucose monitoring company DexCom’s investment in Oura values the company at just over $5 billion. Oura is looking to go public at a valuation above $15 billion. Continue Reading
Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug discovery ecosystem. On September 16, the company confirmed a strategic partnership…
Key Points Interested in ResMed Inc.? Here are five stocks we like better. ResMed targets 12%–14% core EPS growth and 5%–7% core constant-currency revenue growth, supported by higher therapy adoption, resupply activity, product innovation…
Firing on All Cylinders: iRhythm (NASDAQ:IRTC) Q2 Earnings Lead the Way The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how patient monitoring stocks fared…
ResMed Inc. (NYSE:RMD) is well positioned to benefit from the long-term growth of the global obstructive sleep apnea (OSA) treatment market. Likewise, the company remains well positioned to benefit from growing awareness and penetration in…
Sleep device maker ResMed rose Tuesday after the stock notched an upgrade and price target increase on Wall Street. RBC Capital analysts boosted the stock’s rating to Outperform from Sector Perform on Tuesday, while lifting the price targe…
Biotechnology and medical scientific research by Brian A Jackson via Shutterstock ResMed (RMD) shares are pushing higher on Tuesday after a senior RBC Capital Markets analyst upgraded the medical equipment specialist to an "Outperform" rat…
Earlier this year, ResMed reported quarterly results showing revenue of US$1.46 billion, up 8.6% year on year, with adjusted earnings per share ahead of expectations but accompanied by operating margin pressure from higher R&D and supply c…
ResMed (RMD) is projected to attain high-single-digit EPS growth over the next three years, despite PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Resmed RMD benefits from the portfolio reduction of its Residential Care Software segment, which is poised to continue supporting its growth in the coming quarters. The company continues to expand its mask portfolio through product innovat…
[ResMed headquarters in San Diego, CA, USA.] JHVEPhoto RBC Capital Markets on Tuesday upgraded ResMed (RMD [https://seekingalpha.com/symbol/RMD]) to Outperform from Sector Perform and raised its price target to $262 from $244, citing posit…
Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including ResMed (NYSE:RMD) and its peers. Patient monitoring compani…
ResMed headquarters By JHVEPhoto San Diego, California-based ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in t…
Wall Street's major market averages finished lower on Friday after traders and investors digested the latest jobs data, which came in stronger than forecasted. The blue-chip Dow ended 0.5% lower, the benchmark S&P 500 slipped 0.3%, and the…
Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the patient monitoring industry, including Insulet (…
Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images With the second-quarter earnings season now largely behind us, investors are turning their attention to how healthcar…
Healthcare Technology Executive to Lead MatrixCare's Next Phase of Growth and Product Innovation SEATTLE, September 01, 2026--(BUSINESS WIRE)--Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the health…
2 Profitable Stocks Worth Investigating and 1 We Turn Down While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said…
Resmed, Inc. SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan Stanl…
2 S&P 500 Stocks with Promising Prospects and 1 We Ignore While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials,…
ResMed headquarters By JHVEPhoto With a market cap of $33.5 billion, ResMed Inc. (RMD) is a global health technology company that develops innovative solutions to help people live healthier, happier lives through better sleep and breathing…
Reddick, a 13-time NASCAR Cup Series winner and 2026 Daytona 500 Champion, shares how prioritizing sleep health is an important part of his recovery and performance routine SAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, AS…
Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
Resmed, Inc. Nominating and Governance Chair Carol Burt to become Lead Director. Ron Taylor to retire after more than 21 years of service on Resmed's Board of Directors. SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX:…
On August 6, ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 results capping a year of double-digit growth. Quarterly revenue rose 9% to $1.5 billion, and non-GAAP earnings per share jumped 16% to $2.95. For the full fiscal year, whi…
Wall Street ended lower Friday as investors took a pause following the S&P 500’s latest record high, capping a week that saw strength spread across technology, software, small caps, and commodities. The technology-heavy Nasdaq Composite de…
The 5 Most Interesting Analyst Questions From ResMed's Q2 Earnings Call ResMed's second quarter saw steady revenue growth, but the market responded negatively as the company's operating margin declined year over year. Management attributed…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Investor Relations Officer-Salli Schwartz Chairman and Chief Executive Officer-Mick Farrell Chief Financial Officer-Aaron Bloomer Full Confe…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multipl…
In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions shar…
Inogen, Inc. INGN lowered its 2026 revenue outlook after second-quarter results showed continued U.S. channel pressure despite better profitability and international growth. The revision puts more focus on how quickly the company can adapt…
Inogen, Inc. INGN trades at a steep sales-multiple discount even as second-quarter 2026 margins improved and international demand remained firm. The disconnect creates an interesting setup, but the operating recovery is not yet broad-based…